Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer.
about
Adjuvant therapy for pancreas cancer in an era of value based cancer careDynamic Assessment of Value During High-Cost Cancer Treatment: A Response to American Society of Clinical Oncology and European Society of Medical Oncology.Metastatic Colorectal Cancer: A Systematic Review of the Value of Current Therapies.Fatty acid synthase regulates invasion and metastasis of colorectal cancer via Wnt signaling pathwayEfficacy, Safety and Cost of Regorafenib in Patients with Metastatic Colorectal Cancer in French Clinical Practice.Thinking Systematically About the Off-Label Use of Cancer Drugs and Combinations for Patients Who Have Exhausted Proven TherapiesSDHB deficiency promotes TGFβ-mediated invasion and metastasis of colorectal cancer through transcriptional repression complex SNAIL1-SMAD3/4.Comparison of cost-effectiveness of regorafenib and trifluridine/tipiracil combination tablet for treating advanced and recurrent colorectal cancer.Cost effectiveness of regorafenib as second-line therapy for patients with advanced hepatocellular carcinoma.Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States.Is regorafenib providing clinically meaningful benefits to pretreated patients with metastatic colorectal cancer?Adherence and safety of regorafenib for patients with metastatic colorectal cancer: observational real-life study.Value in Colorectal Cancer Treatment: Where It Is Lacking, and Why.The impending financial healthcare burden and ethical dilemma of systemic therapy in metastatic cancer.The high price of anticancer drugs: origins, implications, barriers, solutions.Cost-Effectiveness Analysis of Second-Line Chemotherapy Agents for Advanced Gastric Cancer.Cost-effectiveness of precision medicine in gastrointestinal stromal tumor and gastric adenocarcinoma.Cost-effectiveness analysis of consolidation with brentuximab vedotin for high-risk Hodgkin lymphoma after autologous stem cell transplantation.Cost-effectiveness analysis of apatinib treatment for chemotherapy-refractory advanced gastric cancer.Evolution of regorafenib from bench to bedside in colorectal cancer: Is it an attractive option or merely a "me too" drug?Financial toxicity and implications for cancer care in the era of molecular and immune therapies.
P2860
Q26775916-81668CCC-9E43-4A04-99ED-B13C061BDC9BQ33756769-4AF38B9E-CB44-439C-949E-801C5BFC3DB8Q36553713-8800A5B5-D8D3-4F45-893D-C5ED9717108BQ36893292-FE5B2ED2-99DA-4E47-8E1A-89C34CBCC1F7Q37066657-11C8F8C1-7B26-456F-9A21-30F8327F5711Q37242372-C12773C4-1B92-4AC1-99CC-E7C8CC2A574DQ37396955-212C28AA-1B2F-46B9-8D6E-0D7549DE1270Q37406803-C504F4DC-8833-433B-A6EB-EA3712B2B376Q38702281-9593C123-4D20-4361-9E4A-985273392E51Q38792651-384E5CD2-288C-4BE9-9443-D2DF658D1207Q38796209-77C72160-B318-48A3-B11A-31BE404DC1EEQ38805622-41F3A280-40EB-426F-BE5F-52BD043313D8Q38848793-32F50A43-DF23-4FD6-B95A-145BAD6334A5Q38885867-01EE6366-90FC-44B5-BD54-56C92CA9D553Q38909657-D07CECFF-3651-45F2-871A-D36CAA7D780BQ39015252-767D60C9-BCED-4978-9E4A-F1C3C6817E68Q39453613-5D12A758-C48F-4F19-B55A-1E7F354B921CQ40149586-914FE92B-061A-433B-B875-489431EAA890Q40502728-62FF7F50-9DCB-40C8-8DD1-C482AC3564C0Q52643766-5283C188-E3C3-4C2B-A958-00CC9DCBF487Q55265302-366AF54D-EDE4-4189-B7BC-C4FCF68D4CF7
P2860
Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer.
@ast
Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer.
@en
type
label
Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer.
@ast
Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer.
@en
prefLabel
Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer.
@ast
Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer.
@en
P2093
P2860
P356
P1476
Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer.
@en
P2093
Bassel F El-Rayes
Bilal B Ahmad
Christopher R Flowers
Daniel A Goldstein
David H Howard
Joseph Lipscomb
Qiushi Chen
Turgay Ayer
P2860
P304
P356
10.1200/JCO.2015.61.9569
P407
P577
2015-08-24T00:00:00Z